Limaprost
Modify Date: 2024-01-06 15:18:47
Limaprost structure
|
Common Name | Limaprost | ||
|---|---|---|---|---|
| CAS Number | 74397-12-9 | Molecular Weight | 380.518 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 550.6±50.0 °C at 760 mmHg | |
| Molecular Formula | C22H36O5 | Melting Point | 97-100° | |
| MSDS | Chinese USA | Flash Point | 300.9±26.6 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of LimaprostLimaprost(OP1206) is a PGE1 analog and potent platelet adhesion inhibitor.Target: OthersLimaprost, an alprostadil (prostaglandin E1) analogue, is a vasodilator that increases blood flow and inhibits platelet aggregation. Limaprost is a n analog of PGE1 with structural modifications intended to give a prolonged half-life and greater potency. It is orally active in both guinea pigs and rats at doses of 100 mg/kg as an inhibitor of ADP and collagen induced platelet aggregation. It is 10-1,000 times more potent than PGE1 as a platelet adhesive inhibitor, measured in vitro. Intra-coronary injection (100 ng/kg) or intravenous injection (3 mg/kg) in anesthetized dogs causes vasodilation and increased coronary blood flow by 60-80%. Significant hypotensive effects were seen at 100 and 300 mg/kg orally in rats [1]. |
| Name | (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]hept-2-enoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Limaprost(OP1206) is a PGE1 analog and potent platelet adhesion inhibitor.Target: OthersLimaprost, an alprostadil (prostaglandin E1) analogue, is a vasodilator that increases blood flow and inhibits platelet aggregation. Limaprost is a n analog of PGE1 with structural modifications intended to give a prolonged half-life and greater potency. It is orally active in both guinea pigs and rats at doses of 100 mg/kg as an inhibitor of ADP and collagen induced platelet aggregation. It is 10-1,000 times more potent than PGE1 as a platelet adhesive inhibitor, measured in vitro. Intra-coronary injection (100 ng/kg) or intravenous injection (3 mg/kg) in anesthetized dogs causes vasodilation and increased coronary blood flow by 60-80%. Significant hypotensive effects were seen at 100 and 300 mg/kg orally in rats [1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 550.6±50.0 °C at 760 mmHg |
| Melting Point | 97-100° |
| Molecular Formula | C22H36O5 |
| Molecular Weight | 380.518 |
| Flash Point | 300.9±26.6 °C |
| Exact Mass | 380.256287 |
| PSA | 94.83000 |
| LogP | 3.15 |
| Appearance of Characters | crystalline |
| Vapour Pressure | 0.0±3.4 mmHg at 25°C |
| Index of Refraction | 1.551 |
| Storage condition | −20°C |
| Water Solubility | DMF: soluble |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300 |
| Precautionary Statements | P264-P301 + P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T: Toxic; |
| Risk Phrases | 25 |
| Safety Phrases | 36/37/39-45 |
| RIDADR | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | UK8362500 |
|
OP-1206, a prostaglandin E1 derivative, attenuates the thermal hyperesthesia induced by constriction injury to the sciatic nerve in the rat.
Anesth. Analg. 80(3) , 515-20, (1995) Nerve ischemia induces wallerian degeneration and peripheral neuropathy, the nerve constriction injury induces thermal hyperesthesia. Nerve ischemia is one possible mechanism in the development of the... |
|
|
Inhibition of platelet aggregation by the cAMP-phosphodiesterase inhibitor, cilostamide, may not be associated with activation of cAMP-dependent protein kinase.
Cell. Signal. 4(4) , 453-63, (1992) We examined the involvement of cAMP-dependent protein kinase (A kinase)2 in the inhibition by cilostamide, a specific inhibitor of the low Km cAMP-phosphodiesterase (PDE), on 9,11-epithio-11,12-methan... |
|
|
Correlation between methotrexate-induced intestinal damage and decrease in polyamine content.
Life Sci. 72(6) , 669-76, (2002) A synthetic analog of prostaglandin E(1), OP-1206 [17S, 20-dimethyl-trans-Delta(2)-prostaglandin E(1)] protects the small intestine from the methotrexate (MTX)-induced damage. The purpose of this stud... |
| 17S,20-Dimethyl-trans-delta2-PGE1 |
| (E)-7-((1R,2R,3R)-3-Hydroxy-2-((E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl)-2-heptenoic acid |
| (2E)-7-{(1R,2R,3R)-3-Hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methylnon-1-en-1-yl]-5-oxocyclopentyl}hept-2-enoic acid (non-preferred name) |
| Limaprost |
| (2E)-7-{(1R,2R,3R)-3-Hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonen-1-yl]-5-oxocyclopentyl}-2-heptenoic acid |
| 9-Oxo-11a,15a-dihydroxy-17S,20-dimethylprosta-trans-2,trans-13-dienoic Acid |
| 17S,20-Dimethyl-trans-2,3-didehydro-PGE1 |
| (2E,11a,13E,15S,17S)-11,15-Dihydroxy-17,20-dimethyl-9-oxoprosta-2,13-dien-1-oic Acid |
| 17S-Methyl-w-homo-trans-D2-PGE1 |
| ONO 1206 |
| OP 1206 |